Home | Harrow, Inc.
Mar 24, 2026 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Careers | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Investor Relations | Harrow, Inc.
Mar 3, 2026 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow Launches VEVYE® Access for All
Mar 17, 2025 · I am so pleased that Harrow is addressing the giant elephant in the room – insurance company tactics that often prevent or delay critical care. VEVYE Access for All is a game‑changer, …
Leadership - Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE ...
Mar 3, 2026 · Harrow believes the planned Phase 3 trial represents an important opportunity to further strengthen the clinical and commercial profile of TRIESENCE. The study is designed to generate …
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, …
Jan 23, 2023 · Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company serving ophthalmologists and optometrists by providing FDA-approved branded ophthalmic pharmaceuticals …
Harrow To Report First Quarter 2026 Financial Results After Market ...
5 days ago · Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026 NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a …
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
Apr 16, 2026 · Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions …
Harrow Announces Third Quarter 2025 Financial Results
Sep 30, 2025 · NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results …